-A Polverino Researcher Activity Profile

Research Author Detailed Information 

A Polverino Publication Rate By Year

A Polverino has published 1 paper(s) in 1995, 1 paper(s) in 2006, 3 paper(s) in 2007, 1 paper(s) in 2008, for a total of 6 research publications in total.

A A Polverino Author Information

LAST NAME: polverino

FIRST NAME: A

INITIALS: a

AFFILIATION:

Papers

A Polverino's Publication Record

1. Shk1, a homolog of the Saccharomyces cerevisiae Ste20 and mammalian p65PAK protein kinases, is a component of a Ras/Cdc42 signaling module in the fission yeast Schizosaccharomyces pombe. Year Published: 1995
Cold Spring Harbor Laboratory, NY 11724, USA.
2. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Year Published: 2006
Department of Oncology Research, Amgen, Inc., Thousand Oaks, CA 91320-1799, USA. tonyp@amgen.com
3. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. Year Published: 2007
Premiere Oncology, Santa Monica, CA, USA.
4. Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr. Year Published: 2007
Chemistry Research and Discovery, One Amgen Center Drive Thousand Oaks, CA 91320, USA. celia.dominguez@chdi-inc.org
5. Discovery of N-phenyl nicotinamides as potent inhibitors of Kdr. Year Published: 2007
Chemistry Research and Discovery, One Amgen Center Drive Thousand Oaks, CA 91320, USA. celia.dominguez@chdi-inc.org
6. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors. Year Published: 2008